Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board and Dr. Steven Gelone to the position of Chief Development Officer and member of the Management Team. Most recently, Charles Rowland was the Vice President and Chief Financial Officer of ViroPharma Inc., until its acquisition by Shire plc last year. Most recently, Steven Gelone served as Head of Clinical Research and Development at Spark Therapeutics and was Vice President of Development at ViroPharma Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% |
|
0.00% | +9,900.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 323 | |
+19.54% | 126B | |
+23.02% | 118B | |
+23.26% | 27.87B | |
-19.04% | 20.95B | |
-15.13% | 16.92B | |
-14.49% | 16.18B | |
+9.40% | 14.84B | |
-46.10% | 14.79B | |
+50.37% | 14.08B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics Announces Executive Appointments